Journal article
Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy.
- Bhadhuri A Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland. arjun.bhadhuri@unibas.ch.
- Kind P Academic Unit for Health Economics, Institute for Health Sciences, University of Leeds, Leeds, UK.
- Salari P Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.
- Jungo KT Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
- Boland B Institut de Recherche Santé et Société, Université Catholique de Louvain, Brussels, Belgium.
- Byrne S Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland.
- Hossmann S CTU Bern, University of Bern, Bern, Switzerland.
- Dalleur O Institut de Recherche Santé et Société, Université Catholique de Louvain, Brussels, Belgium.
- Knol W Department of Geriatric Medicine and Expertise Centre Pharmacotherapy in Old Persons, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Moutzouri E Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
- O'Mahony D Department of Medicine (Geriatrics), School of Medicine, University College Cork, Cork, Ireland.
- Murphy KD Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland.
- Wisselink L Department of Geriatric Medicine and Expertise Centre Pharmacotherapy in Old Persons, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Rodondi N Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
- Schwenkglenks M Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.
- 2020-09-30
Published in:
- Health and quality of life outcomes. - 2020
English
BACKGROUND
The EQ-5D-3L and EQ-5D-5L are two generic health-related quality of life measures, which may be used in clinical and health economic research. They measure impairment in 5 aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The aim of this study was to assess the performance of the EQ-5D-3L and EQ-5D-5L in measuring the self-reported health status of older patients with substantial multimorbidity and associated polypharmacy.
METHODS
Between 2017 and 2019, we administered EQ-5D-3L and EQ-5D-5L to a subset of patients participating in the OPERAM trial at 6 months and 12 months after enrolment. The OPERAM trial is a two-arm multinational cluster randomised controlled trial of structured medication review assisted by a software-based decision support system versus usual pharmaceutical care, for older people (aged ≥ 70 years) with multimorbidity and polypharmacy. In the psychometric analyses, we only included participants who completed the measures in full at 6 and 12 months. We assessed whether responses to the measures were consistent by assessing the proportion of EQ-5D-5L responses, which were 2 or more levels away from that person's EQ-5D-3L response. We also compared the measures in terms of informativity, and discriminant validity and responsiveness relative to the Barthel Index, which measures independence in activities of daily living.
RESULTS
224 patients (mean age of 77 years; 56% male) were included in the psychometric analyses. Ceiling effects reported with the EQ-5D-5L (22%) were lower than with the EQ-5D-3L (29%). For the mobility item, the EQ-5D-5L demonstrated better informativity (Shannon's evenness index score of 0.86) than the EQ-5D-3L (Shannon's evenness index score of 0.69). Both the 3L and 5L versions of EQ-5D demonstrated good performance in terms of discriminant validity, i.e. (out of all items of the EQ-5D-3L and EQ-5D-5L, the pain/discomfort and anxiety/depression items had the weakest correlation with the Barthel Index. Both the 3L and 5L versions of EQ-5D demonstrated good responsiveness to changes in the Barthel Index.
CONCLUSION
Both EQ-5D-3L and EQ-5D-5L demonstrated validity and responsiveness when administered to older adults with substantial multimorbidity and polypharmacy who were able to complete the measures.
The EQ-5D-3L and EQ-5D-5L are two generic health-related quality of life measures, which may be used in clinical and health economic research. They measure impairment in 5 aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The aim of this study was to assess the performance of the EQ-5D-3L and EQ-5D-5L in measuring the self-reported health status of older patients with substantial multimorbidity and associated polypharmacy.
METHODS
Between 2017 and 2019, we administered EQ-5D-3L and EQ-5D-5L to a subset of patients participating in the OPERAM trial at 6 months and 12 months after enrolment. The OPERAM trial is a two-arm multinational cluster randomised controlled trial of structured medication review assisted by a software-based decision support system versus usual pharmaceutical care, for older people (aged ≥ 70 years) with multimorbidity and polypharmacy. In the psychometric analyses, we only included participants who completed the measures in full at 6 and 12 months. We assessed whether responses to the measures were consistent by assessing the proportion of EQ-5D-5L responses, which were 2 or more levels away from that person's EQ-5D-3L response. We also compared the measures in terms of informativity, and discriminant validity and responsiveness relative to the Barthel Index, which measures independence in activities of daily living.
RESULTS
224 patients (mean age of 77 years; 56% male) were included in the psychometric analyses. Ceiling effects reported with the EQ-5D-5L (22%) were lower than with the EQ-5D-3L (29%). For the mobility item, the EQ-5D-5L demonstrated better informativity (Shannon's evenness index score of 0.86) than the EQ-5D-3L (Shannon's evenness index score of 0.69). Both the 3L and 5L versions of EQ-5D demonstrated good performance in terms of discriminant validity, i.e. (out of all items of the EQ-5D-3L and EQ-5D-5L, the pain/discomfort and anxiety/depression items had the weakest correlation with the Barthel Index. Both the 3L and 5L versions of EQ-5D demonstrated good responsiveness to changes in the Barthel Index.
CONCLUSION
Both EQ-5D-3L and EQ-5D-5L demonstrated validity and responsiveness when administered to older adults with substantial multimorbidity and polypharmacy who were able to complete the measures.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s12955-020-01564-0
- PMID 32993637
- Persistent URL
- https://sonar.ch/global/documents/228146
Statistics
Document views: 8
File downloads: